Cell and Gene Manufacturing and Logistics

  1. Strengthening Bioprocessing Supply Chains: The SaniSure Manufacturing Advantage 9/27/2026

    Hidden costs, regulatory demands, and global disruptions challenge bioprocessing supply chains. Learn how domestic sourcing can improve reliability, quality oversight, and risk management.

  2. Advanced Therapies CDMO: Manufacturing Advanced Therapies To Reach More Patients 9/27/2026

    This advanced therapies CDMO invests in automation and digital systems to cut cell therapy costs, supporting partners from IND to commercial supply.

  3. Gene Editing Tools & Services: A Faster Path To The Right Edit 9/26/2026

    AI-driven enzyme discovery, protein engineering, and multiple gene-editing modalities can accelerate feasibility testing and support data-driven decisions for emerging therapeutic programs.

  4. Inside Scaling Next-Gen MSCs Without Scaling Risk 9/25/2026

    Here's why scaling MSC therapies requires maintaining product consistency, potency, and comparability as manufacturing evolves.

  5. Annex 1 In Practice: Turning CCS Into Cleanroom Design 9/24/2026

    Learn how embedding a contamination control strategy into early facility design mitigates risk, protects product quality, and ensures regulatory compliance.

  6. Iterative Engineering And Optimization Strategies For Maximizing LNP-Mediated Gene Editing In The Liver 9/24/2026

    Learn how iterative optimization of mRNA modifications, guide RNA chemistry, and LNP formulation drives gains in gene editing potency across nuclease, base editing, and reverse transcriptase modalities.

  7. CRISPR Nucleases And Proprietary Reverse Transcriptases For Precise Gene Editing 9/24/2026

    Mining a database of over 10 billion natural proteins has yielded proprietary reverse transcriptases and engineered RT editing systems capable of achieving precise gene editing in vivo.

  8. Engineering Hepatocyte-Targeted LNPs For RNA And DNA Delivery To Primary Human T Cells 9/24/2026

    Learn how LNP formulations can be adapted to achieve highly efficient RNA and DNA transfection in primary human T cells, outperforming electroporation across critical gene-engineering endpoints.

  9. Comprehensive Off-Target Assessment Strategies For CRISPR-Based Genome Editing Therapeutics 9/24/2026

    Off-target safety evaluation for CRISPR therapeutics requires integrating multiple orthogonal methods, as no single approach captures the full spectrum of editing events across modalities and cell types.

  10. CMC Considerations For CRISPR And Next-Gen Technologies 9/24/2026

    CMC considerations for CRISPR and next-generation gene editing technologies are examined through the lens of LETI-101, a preclinical AAV5-delivered CRISPR candidate targeting Huntington's disease.